Hudson Bay Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Hudson Bay Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$4.08M	–	1037
2023 Q2	$4.08M	Buy	+40,000	New	+$3.79M	0.03%	355
2023 Q1	–	Sell	-20,000	Closed	-$760K	–	1116
2022 Q4	$760K	Buy	+20,000	New	+$688K	0.01%	707
2021 Q2	–	Sell	-6,205	Closed	-$619K	–	1095
2021 Q1	$619K	Buy	+6,205	New	+$724K	0.01%	719

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hudson Bay Capital Management's RETA Position: Q3 2023 in Review

Hudson Bay Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 40,000 shares — an estimated $4.08M sold.

Hudson Bay Capital Management first reported a position in RETA in Q1 2021 and held it in 3 quarters. The position peaked at $4.08M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Hudson Bay Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 40,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4.08M.
Hudson Bay Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
Hudson Bay Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.08M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Hudson Bay Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.